National Jewish to Present at BIO Convention

National Jewish Medical and Research Center, the #1 respiratory hospital in the U.S. for the 8 consecutive years (U.S. News & World Report), announced today that it will present three posters on April 10 at the Biotechnology Industry Organization Annual Convention in Chicago, IL. The posters describe cutting-edge technologies developed at National Jewish and were selected by BIO for presentation Monday from 1 p.m. to 4 p.m. at the Innovation Corridor.

Emmanuel Hilaire, PhD and Pearlanne Zelarney, of the Intellectual Property and Technology Commercialization Program at National Jewish, will present:

•  Novel Angiogenic Factors and a TGF-beta Inhibitor as Cancer Therapeutics

•  Method to Identify MHC-Presented Peptide Epitopes for T Cells

•  Modulation of Oxidative Stress in the Treatment of Lung Disease and Cancer

In addition to the poster session, National Jewish will participate in one-on-one partnering meetings with more than 35 biotech companies at the Business Forum and will be represented as one of the state’s preeminent research organizations in the State of Colorado Pavilion, booth #1673.

“Partnerships with the private sector are important to National Jewish,” said Brad Brockbank, manager of the Intellectual Property and Technology Commercialization Program. “Concern for the needs of patients motivates us to discover new and better diagnostic tests and therapies. The translation of our laboratory science requires active partnerships with companies that have the skills and resources that complement ours.”

“The BIO convention is a unique and valuable venue for National Jewish to explore potential partnerships with biotech companies worldwide, and to showcase our research and clinical expertise,” added Dr. Hilaire.

The Intellectual Property and Technology Commercialization Program at National Jewish has a portfolio of technologies available for out-licensing and is interested in developing collaborations with the private sector in the form of research sponsorship and/or technology licensing & development. National Jewish has ongoing collaborative research and license arrangements with a number of biopharmaceutical companies in the U.S., Europe, and Japan.

About National Jewish:

National Jewish is the only medical and research center in the United States devoted entirely to respiratory, allergic and immune-system diseases, including asthma, tuberculosis, emphysema, severe allergies, cystic fibrosis, lupus and other autoimmune diseases. U.S. News & World Report has named National Jewish the best respiratory hospital in the nation for eight consecutive years.

National Jewish’s basic research programs were also recently ranked among the best in the world. Thomson ISI evaluates the impact of an institution’s research by measuring how often its journal articles are cited by other authors. In 2004, National Jewish ranked twelfth, fifteenth and twenty-second respectively in molecular biology and genetics, biology and biochemistry, and immunology among thousands of academic and commercial institutions around the world, including large pharmaceutical companies.

National Jewish physician/researchers participate in numerous National Institutes of Health studies that evaluate new and existing treatments for asthma, chronic obstructive pulmonary disease, allergies and other diseases. They also serve on several NIH advisory boards that write guidelines for treatment of respiratory and allergic diseases. National Jewish’s basic research program has also been ranked among the world’s best.